title: Effect of Rebamipide Ophthalmic Suspension on Intraocular Light Scattering for Dry Eye After Corneal Refractive Surgery.
abstract: OBJECTIVE
  To assess the changes in intraocular scattering before and after instillation of rebamipide ophthalmic suspension in patients with dry eye after corneal refractive surgery.
  
  
  METHODS
  This study enrolled 60 eyes of 30 dry eye patients undergoing corneal refractive surgery. Patients were randomly assigned to start topical administration of rebamipide ophthalmic suspension (rebamipide group) or artificial tears (control group) 4 times daily for 4 weeks. Tear secretion, tear break-up time (TBUT), and the fluorescein score were measured before and after treatment. Intraocular light scattering was also measured as the objective scattering index (OSI) at 0.5-second intervals over 10 seconds.
  
  
  RESULTS
  In the rebamipide group, the Schirmer I test, TBUT, and fluorescein score improved significantly, from 11.4 ± 9.0 mm, 2.2 ± 0.7 seconds, and 4.3 ± 1.3 to 14.9 ± 7.4 mm, 4.5 ± 1.7 seconds, and 1.9 ± 1.0, respectively (P = 0.006, P < 0.001, P < 0.001, Wilcoxon signed rank test). We found significant improvements in OSI at 5.0 to 10.0 seconds after blinking (5-8 seconds, P = 0.01; 9 seconds, P = 0.02; 10 seconds, P < 0.001). The mean OSI, the OSI change rate, and the OSI slope of the linear regression line improved significantly, from 2.73 ± 1.52, 74.7 ± 69.5%, and 0.10 ± 0.12 to 2.19 ± 1.19, 28.6 ± 48.7%, and 0.04 ± 0.08, respectively (P = 0.02, 0.003, and 0.03).
  
  
  CONCLUSIONS
  Rebamipide ophthalmic suspension was effective for improving both ocular surface parameters and optical quality in patients with dry eye undergoing corneal refractive surgery, suggesting that it may hold promise for the treatment of such patients.
authors.affiliation: Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Igarashi
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Kamiya
authors.forename: Hidenaga
authors.initials: H
authors.lastname: Kobashi
authors.forename: Kimiya
authors.initials: K
authors.lastname: Shimizu
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D020731:Keratomileusis, Laser In Situ; D054018:Lasers, Excimer / Q000627:therapeutic use; D008027:Light; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000601:surgery; D011183:Postoperative Complications / Q000188:drug therapy / Q000503:physiopathology; D011446:Prospective Studies; D015363:Quinolones / Q000627:therapeutic use*; D012542:Scattering, Radiation; D013535:Suspensions; D013666:Tears / Q000502:physiology; D055815:Young Adult
chemical_list: D000897:Anti-Ulcer Agents; D015363:Quinolones; D013535:Suspensions; C052785:rebamipide; D000409:Alanine